Stockreport

Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression [Yahoo! Finance]

Neumora Therapeutics, Inc.  (NMRA) 
PDF Navacaprant is also currently in Phase 3 development for the treatment of MDD with data from KOASTAL-1 anticipated in the fourth quarter of 2024 WATERTOWN, Mass., May [Read more]